Shengwei Li

Title: Innovations of Shengwei Li

Introduction

Shengwei Li is a notable inventor based in Chengdu, China. He has made significant contributions to the field of biotherapeutics, particularly through his work on recombinant fusion proteins. With a total of 2 patents, his innovations are paving the way for advancements in medical treatments.

Latest Patents

Shengwei Li's latest patents focus on the development of human neuregulin-1 (NRG-1) recombinant fusion protein compositions. These inventions relate to a recombinant fusion protein that comprises a fragment of the cardioprotective protein neuregulin-1 (NRG-1) fused to a monoclonal antibody (mAb) backbone. The methods of use for these compositions involve treating diseases or conditions in subjects by administering a therapeutically effective amount of the recombinant fusion protein or the pharmaceutical composition that includes it.

Career Highlights

Throughout his career, Shengwei Li has worked with prominent companies in the biotherapeutics sector. Notable among these are Salubris Biotherapeutics, Inc. and Salubris (Chengdu) Biotech Co., Ltd. His work in these organizations has contributed to the advancement of innovative therapies.

Collaborations

Shengwei Li has collaborated with several professionals in his field, including John H Li and Dixiang Luo. These collaborations have further enhanced his research and development efforts.

Conclusion

Shengwei Li's contributions to the field of biotherapeutics through his patents and collaborations highlight his role as an influential inventor. His work continues to impact the medical community positively.